Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Individuals with type 2 diabetes and obesity face a high risk for developing cardiovascular disease and experiencing major cardiac events or conditions, including myocardial infarction, stroke, heart failure, cardiovascular death, and peripheral arterial disease
These meds have historically run upward of $1,000 without insurance (and coverage is still limited)though both Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) have recently cut that price in half, to $499 a month, for folks without coverage who opt in to direct-pay programs with the drugmakers
Targeting the Notch and TGF- signaling pathways to prevent retinal fibrosis in vitro and in vivo
SURPASS-2 directly compared tirzepatide 15 mg to semaglutide 1 mg over 40 weeks
US$ 28.68
US$ 26.22
US$ 22.47
%20(1).png)
US$ 23.99
